Dyne Therapeutics Inc (DYN)
28.37
-0.13
(-0.46%)
USD |
NASDAQ |
Mar 28, 16:00
28.96
+0.59
(+2.08%)
After-Hours: 20:00
Dyne Therapeutics Cash from Financing (Quarterly): 0.147M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.147M |
September 30, 2023 | 0.454M |
June 30, 2023 | 24.91M |
March 31, 2023 | 28.82M |
December 31, 2022 | 37.20M |
September 30, 2022 | 0.07M |
June 30, 2022 | 0.099M |
March 31, 2022 | 0.018M |
Date | Value |
---|---|
December 31, 2021 | 0.089M |
September 30, 2021 | 0.457M |
June 30, 2021 | 0.025M |
March 31, 2021 | 157.25M |
December 31, 2020 | -11.19M |
September 30, 2020 | 379.98M |
June 30, 2020 | 0.00 |
March 31, 2020 | 11.91M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.19M
Minimum
Dec 2020
379.98M
Maximum
Sep 2020
39.39M
Average
0.3005M
Median
Cash from Financing (Quarterly) Benchmarks
First Wave BioPharma Inc | 5.388M |
ABVC BioPharma Inc | 0.0874M |
NexImmune Inc | 0.00 |
Voyager Therapeutics Inc | 0.46M |
Applied Therapeutics Inc | 29.45M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -35.01M |
Cash from Investing (Quarterly) | 26.20M |
Free Cash Flow | -188.89M |
Free Cash Flow Per Share (Quarterly) | -0.5714 |
Free Cash Flow Yield | -11.16% |